Do Frankincense and Myrrh Help Neuropathy?

Frankincense and myrrh show genuine promise for neuropathic pain in laboratory research, but the honest answer right now is that the evidence comes almost entirely from animal studies, not from human clinical trials focused on neuropathy. Several well-designed mouse studies have found that combined frankincense-myrrh extracts reduce the hallmarks of nerve pain, and researchers have identified plausible biological pathways that explain why. The gap between “it works in mice” and “it will help your neuropathy” remains large, though, and anyone considering these resins should understand both what the science actually shows and where it falls short.

What the Animal Research Actually Found

The most directly relevant evidence comes from studies using mouse models of neuropathic pain, typically induced by surgically constricting a nerve. In one widely cited study, mice given a frankincense-myrrh combination showed significant relief from both thermal hypersensitivity (overreacting to heat) and mechanical allodynia (feeling pain from a normally painless touch). The treatment reduced markers of neuroinflammation in the spinal cord, specifically dampening activity in a signaling chain that drives nerve-related immune activation.¹

A separate study using a water-based extract of the same two resins confirmed these findings. Mice with nerve injuries showed reduced pain responses after treatment, and the researchers traced the effect to changes in a specific pain receptor called TRPV1, which is involved in how nerves detect painful heat and chemical irritants. The extract brought elevated TRPV1 levels back toward normal in both the gene-expression and protein measurements.²

More recent research has pushed the findings further. A 2025 study examined two specific compounds derived from frankincense and myrrh respectively, finding that their combination reduced pain sensitivity more strongly than either alone, and promoted the repair of structures around damaged nerve cells in the spinal cord.³

How Frankincense and Myrrh Act on Nerve Pain

Neuropathic pain is fundamentally different from the pain you feel when you stub your toe. In neuropathy, the nerves themselves are damaged or dysfunctional, and the body’s immune cells in the spinal cord (called microglia and astrocytes) become chronically activated. This sustained activation creates a feedback loop: immune cells keep releasing inflammatory signals that make the nerves even more sensitive, which triggers more immune activity, and so on. The result is pain that persists long after any original injury has healed.

Frankincense and myrrh appear to interrupt this loop at multiple points. The animal research shows they suppress a signaling pathway that acts as an alarm system for the immune cells in the spinal cord, reducing the release of inflammatory molecules.¹ At the same time, they dial down TRPV1, the receptor that makes damaged nerves hypersensitive to stimuli.² Think of it as quieting both the alarm system and the volume knob on pain signals simultaneously.

More broadly, boswellic acids from frankincense have been shown to interact with several key inflammatory pathways, including those involving the enzymes that produce pain-related compounds in the body.⁴ One practical advantage that researchers have noted is that boswellic acids can cross the blood-brain barrier, the tightly regulated membrane that prevents most substances from reaching the brain and spinal cord. Standard anti-inflammatory drugs often cannot do this effectively, which limits their usefulness for nerve pain that originates in the central nervous system.⁵

Why the Two Resins Are Paired Together

Frankincense and myrrh have been used as a pair in traditional medicine for centuries, and modern chemistry is beginning to explain why. When the two resins are combined, their chemical profiles actually change. Some compounds increase in concentration, others decrease, certain native chemicals disappear, and entirely new chemical components emerge from the interaction.⁶

The research suggests the paired resins produce stronger pain-relieving and anti-inflammatory effects than either one alone. The 2025 study on frankincense-derived KBA and myrrh-derived Z-guggulsterone explicitly found that combining the two compounds produced a more pronounced reduction in pain sensitivity than either individually, along with greater changes in immune cell behavior and nerve-protective structures in the spinal cord.³ The practical implication is that if you are considering one of these resins for pain, the evidence slightly favors using both rather than either alone.

The Active Ingredients That Matter

Understanding which compounds do the work is useful if you are trying to evaluate supplement labels or compare products. In frankincense, the key active compounds are boswellic acids, a family of molecules found in the tree resin. Among these, AKBA (acetyl-11-keto-beta-boswellic acid) is considered the most potent and well-studied.⁷ AKBA has been specifically investigated for its effects on the nervous system, with research exploring its role in conditions involving neuroinflammation and nerve damage.⁸

Interestingly, research suggests that whole frankincense extracts enriched in boswellic acids may work better than pure AKBA alone.⁹ This is a common finding in herbal medicine research: isolated compounds sometimes underperform the complex extract they were taken from, because other compounds in the mixture contribute to or enhance the effect.

In myrrh, the pain-relevant compounds are different in character. They are primarily sesquiterpenes with furanodiene structures, including curzerene and furanoeudesma-1,3-diene. These compounds have been linked to myrrh’s analgesic effects since ancient times, and standardized extracts with high furanodiene content have been developed for research purposes.¹⁰ Myrrh also contains a range of other biologically active compounds, including terpenoids and steroids, and has demonstrated anti-inflammatory, antioxidant, and neuroprotective properties in various studies.¹¹

The Distance Between Lab Results and Your Neuropathy

Here is where an honest assessment has to get uncomfortable. Every neuropathy-specific study described above was conducted in mice, not people. The mouse models involve surgically induced nerve injury, which is a reasonable approximation of certain types of human neuropathy but far from a perfect match. Human neuropathy comes in many forms: diabetic neuropathy (by far the most common), chemotherapy-induced neuropathy, neuropathy from autoimmune conditions, post-surgical nerve damage, and idiopathic cases where the cause is never identified. Whether frankincense and myrrh work differently across these types is simply unknown.

Mouse studies are an essential first step in evaluating any treatment, and the neuropathy research on frankincense and myrrh is of reasonable quality, with identified mechanisms and consistent findings across multiple studies. But the history of drug development is full of compounds that performed well in animal models and failed in human trials. Mice metabolize substances differently, their nervous systems are simpler, and the psychological component of human pain perception has no real analog in rodent studies.

There are human trials of boswellic acids for related conditions like osteoarthritis and brain inflammation after stroke, and one pilot study found that boswellic acids crossed the blood-brain barrier and reduced inflammatory markers in stroke patients.⁵ These adjacent findings are encouraging because they confirm that boswellic acids do produce anti-inflammatory effects in the human central nervous system. But “reduces inflammation in the brain” and “relieves neuropathy symptoms” are not the same claim, and we should not pretend they are.

What This Means If You Have Neuropathy Now

If you are living with neuropathic pain and considering frankincense and myrrh, the realistic picture looks like this: there is a plausible scientific rationale for why these resins could help, supported by consistent animal data and a few human studies on related conditions. There is no published clinical trial specifically testing frankincense, myrrh, or their combination for neuropathy in humans. That does not mean they cannot help; it means the evidence is not strong enough for anyone to make confident claims about how much they might help, which types of neuropathy they would work best for, or what dose would be effective.

People with neuropathy are often in a difficult position because conventional treatments are only partially effective for many patients. Medications like gabapentin and pregabalin help some people but leave others with inadequate relief and side effects. In that context, trying a well-characterized botanical supplement with a reasonable safety profile is not unreasonable, but it is important to maintain realistic expectations and to not abandon treatments that provide partial relief in favor of something that has not been proven in humans.

If you do try frankincense supplements, look for products that specify the species (Boswellia serrata is the most studied), identify the plant part used (gum resin), and state the boswellic acid content. The reason this matters brings us to a serious practical problem.

The Supplement Quality Problem

A survey of the top-selling frankincense (Boswellia) supplements in Europe and the United States found alarming inconsistencies. Out of seventeen products tested, only five disclosed all the relevant information about their extract, including the species, the part of the plant used, and the boswellic acid content. Roughly 40% of the products did not match what their labels claimed.¹²

The problems ranged from minor to absurd. One Italian product contained none of the six characteristic boswellic acids at all, suggesting it either did not contain frankincense or used a species with a completely different chemical profile. An American product contained only traces. Other products used different Boswellia species than what was labeled, or contained enriched extracts without disclosing the manipulation. Two products that did contain boswellic acids had quantities different from what their labels stated.¹²

This is not unique to frankincense; supplement quality control is a known issue across the industry. But it means that even if frankincense and myrrh do help neuropathy, many commercial products may not contain enough of the active compounds to produce a meaningful effect. If you are spending money on these supplements based on the research described in this article, the research used carefully prepared, chemically characterized extracts. The capsule you buy online may bear little resemblance to what was tested in the lab.

Bioavailability and Why It Complicates Things

Even when a supplement contains what the label claims, there is another hurdle: boswellic acids are not easily absorbed by the body. They are fat-soluble and have relatively low bioavailability when taken orally, meaning a large fraction of what you swallow never reaches your bloodstream in active form. Researchers have identified this as a major challenge in translating the laboratory findings to clinical use.⁴

Various strategies are being explored to improve absorption, including formulating boswellic acids with fats or lipid-based delivery systems, and some commercial products already use such formulations. Taking frankincense supplements with a fatty meal could theoretically improve absorption, though the degree of improvement in the context of neuropathy specifically has not been quantified. The mouse studies used controlled doses delivered directly, sidestepping the absorption question that human users face.

Nerve Repair Versus Pain Management

One of the more intriguing findings from recent research is that frankincense and myrrh compounds may do more than just mask pain. The 2025 study found evidence that the combination promoted remodeling of perineuronal nets, which are structural scaffolds surrounding nerve cells that play a role in nerve function and plasticity. The treatment also influenced how immune cells in the spinal cord shifted between inflammatory and protective states.³

If confirmed in further research, this would represent something different from how most pain medications work. Standard neuropathy drugs like gabapentin primarily suppress pain signals without addressing the underlying nerve damage. A treatment that both reduces pain and supports nerve repair would be considerably more valuable. That said, this finding is from a single animal study and should be treated as an intriguing early signal rather than established fact. The gap between observing nerve-related structural changes in mouse spinal cords and demonstrating functional nerve regeneration in human patients is vast.

For people with neuropathy who are watching this space, the research trajectory is worth following. The mechanisms identified in mouse studies provide clear targets for future clinical trials, and the long history of safe human use of both resins in traditional medicine lowers (though does not eliminate) the safety hurdle. What is missing is the clinical data that would tell you whether the dose and form of frankincense and myrrh available to consumers today can reproduce the effects seen under controlled laboratory conditions. Until those trials are conducted, the answer to whether these ancient resins help neuropathy remains genuinely promising but scientifically incomplete.